Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: Systematic review and meta-analysis

International Journal of Biological Markers

Volumn 31, Issue 1, 2016, Pages e1-e10

  Pyo, Jung Soo ^a   Sohn, Jin Hee ^a   Kim, Woo Ho ^b  

^a School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Diagnostic test accuracy review; Gastric carcinoma; HER2; Immunohistochemistry; In situ hybridization; Meta analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

AREA UNDER THE CURVE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; SYSTEMATIC REVIEW; BIOSYNTHESIS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; PATHOLOGY; PREDICTIVE VALUE; STOMACH NEOPLASMS;

BIOMARKERS, TUMOR; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84959360983     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000171     Document Type: Review

References (56)

1. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon, France: International Agency for Research on Cancer; 2010.
2. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-1529.
3. Kim MA, Jung JE, Lee HE, Yang HK, Kim WH. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. Hum Pathol. 2013;44(4):487-494.
4. Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
5. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51(8):1371-1379.
6. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15(1):65-71.
7. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007;38(9):1386-1393.
8. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.
9. Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008;8(1):363.
10. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and diseasespecific survival in gastric carcinoma patients. Br J Cancer. 2009; 100(3):487-493.
11. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63(9):839-842.
12. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro- oesophageal adenocarcinomas assessed by two rabbitmonoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58(3): 383-394.
13. Cidon EU, Centeno RG, Lagarto EG, Peral JI. HER-2 evaluation in a specific gastric cancer population with the highest rate of mortality in Spain. J Oncol. 2011;2011:391564.
14. Im SA, Kim JW, Kim JS, et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol. 2011; 20(2):94-100.
15. Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59(5):822-831.
16. Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59(5):832-840.
17. Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordr). 2011;34(2):89-95.
18. Tafe LJ, Janjigian YY, Zaidinski M, et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med. 2011;135(11): 1460-1465.
19. Wang YK, Gao CF, Yun T, et al. Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet. 2011;4(1):14.
20. Yan B, Yau EX, Choo SN, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 2011;64(10):880-883.
21. Cho EY, Srivastava A, Park K, et al. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology. 2012;44(3):216-220.
22. Kim JW, Im SA, Kim M, et al. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res. 2012; 32(4):1547-1553.
23. Kiyose S, Igarashi H, Nagura K, et al. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int. 2012;62(11):728-734.
24. Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20(1):13-24.
25. Liu W, Zhong S, Chen J, Yu Y. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and earlystage gastric cancer patients. J Clin Gastroenterol. 2012;46(4): e31-e37.
26. Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol. 2012;43(3): 413-422.
27. Yang J, Luo H, Li Y, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62(1):221-228.
28. Zhou F, Li N, Jiang W, et al. Prognosis significance of HER-2/ neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol. 2012;10(1):274.
29. Cho J, Jeong J, Sung J, et al. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. Ann Surg Oncol. 2013;20(Suppl 3):S477-S484.
30. Cruz-Reyes C, Gamboa-Dominguez A. HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype. Int J Surg Pathol. 2013;21(3):240-246.
31. Gasljevic G, Lamovec J, Contreras JA, Zadnik V, Blas M, Gasparov S. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding wholetissue sections with a supplemental FISH study. Pathol Oncol Res. 2013;19(4):855-865.
32. Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24(7):1754-1761.
33. Grin A, Brezden-Masley C, Bauer S, Streutker CJ. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH. Appl Immunohistochem Mol Morphol. 2013;21(6):561-566.
34. He WL, Li YH, Yang DJ, et al. Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol. 2013;39(2):141-149.
35. Kataoka Y, Okabe H, Yoshizawa A, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16(1):84-93.
36. Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013;49(6):1448-1457.
37. Pala EE, Bayol U, Ozguzer A, Akman O. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™). Pathol Res Pract. 2013;209(9):548-554.
38. Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci. 2013;58(2):397-404.
39. Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013; 8(1):76.
40. Xu CC, Yue L, Wei HJ, et al. Significance of TFF3 protein and Her- 2/neu status in patients with gastric adenocarcinoma. Pathol Res Pract. 2013;209(8):479-485.
41. Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2- based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17(1):34-42.
42. Chen M, Li Y, Ming Z, Biao A, Zheng LX. Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. Contemp Oncol (Pozn). 2014;18(2): 95-99.
43. Kandel C, Leclair F, Bou-Hanna C, Laboisse CL, Mosnier JF. Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas. J Clin Pathol. 2014;67(4):307-312.
44. Kimura Y, Oki E, Yoshida A, et al. Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. Anticancer Res. 2014;34(8): 4207-4212.
45. Selcukbiricik F, Erdamar S, Buyukunal E, Serrdengecti S, Demirelli F. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy? Asian Pac J Cancer Prev. 2014;15(24):10607-10611.
46. Tang D, Liu CY, Shen D, et al. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. Onco Targets Ther. 2015;8: 7-14.
47. Werner D, Battmann A, Steinmetz K, et al. The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing. J Transl Med. 2014; 12(1):160.
48. Yoshida H, Yamamoto N, Taniguchi H, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465(2):145-154.
49. Zhu GJ, Xu CW, Fang MY, Zhang YP, Li Y. Detection of Her-2/neu expression in gastric cancer: quantitative PCR versus immunohistochemistry. Exp Ther Med. 2014;8(5):1501-1507.
50. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta- DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6(1):31.
51. Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011;12(6):1417-1423.
52. Chen C, Yang JM, Hu TT, et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res. 2013;44(5):380-389.
53. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.
54. Leeflang MM, Deeks JJ, Takwoingi Y, Macaskill P. Cochrane diagnostic test accuracy reviews. Syst Rev. 2013;2(1):82.
55. Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer. 2014 Apr 10 [Epub ahead of print].
56. Asioli S, Maletta F, Verdun di Cantogno L, et al. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer. Hum Pathol. 2012;43(11): 2070-2079.